Go.XMC.pl Muzyka WEB 2.0 - Palobiofarma completed the dose escalation part of the Phase I study with. : Epsilon mode

.:: Popularne ::.

Points

Palobiofarma completed the dose escalation part of the Phase I study with.

Medibiofarma announced the nomination of a new Development Candidate, the compound MBF-118, a novel PPAR-y receptor antagonist for the treatment of bladder cancer. The compound will start IND enabling studies the second quarter 2018.

Temat: Instrumenty

Komentarze (0)
Kto zaglosowal na ten odsylacz?
Powiadom Znajomego

.:: Popularne ::.

.:: Ads ::.

.:: QNews ::.

.:: Kategorie ::.

.:: Music News ::.